Details werden geladen...
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Manila Times
FDA sets updated PDUFA date of December 27, 2026
Ähnliche Seiten
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain o...
https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-elsunersen-for-the-treatment-of-seizures-associated-with-scn2a-developmental-and-epileptic-encephalopathy-caused-by-gain-of-function-variants/2370058
PRESS RELEASE: NACON: Extension of the observation period for the judicial reorganisation proceedings | The Manila Times
https://www.manilatimes.net/2026/05/28/tmt-newswire/globenewswire/press-release-nacon-extension-of-the-observation-period-for-the-judicial-reorganisation-proceedings/2353022Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | The Manila Times
https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2357293FTI Consulting Announces Increase and Extension of Revolving Credit Facility | The Manila Times
https://www.manilatimes.net/2026/07/01/tmt-newswire/globenewswire/fti-consulting-announces-increase-and-extension-of-revolving-credit-facility/2376629Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. | The Manila Times
https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/revolution-medicines-announces-planned-leadership-transition-for-steve-kelsey-md/2370055